Cargando…

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer

Background: Although intrinsic molecular subtype has been widely used, there remains great clinical heterogeneity of prognosis in the estrogen receptor (ER)- and/or progesterone receptor (PR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC). Methods: The trans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Feng, Zheng, Fangchao, Han, Ying, Zhao, Jiuda, Yuan, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201983/ https://www.ncbi.nlm.nih.gov/pubmed/35721151 http://dx.doi.org/10.3389/fphar.2022.820437

Ejemplares similares

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
por: Shen, Guoshuang, et al.
Publicado: (2021)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma
por: Chen, Yi, et al.
Publicado: (2022)

Cuproptosis/ferroptosis-related gene signature is correlated with immune infiltration and predict the prognosis for patients with breast cancer
por: Li, Jixian, et al.
Publicado: (2023)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Clinicopathological Differences and Prognostic Value of Hypoxia-Inducible Factor-2α Expression for Gastric Cancer: Evidence From Meta-Analysis
por: Zheng, Fangchao, et al.
Publicado: (2016)

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
por: Parise, Carol A., et al.
Publicado: (2014)

Title: Multi-Omics and Immune Landscape of Proliferative LncRNA Signatures: Implications for Risk Stratification and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Chi, et al.
Publicado: (2022)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma
por: Zhang, Mingwei, et al.
Publicado: (2020)

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
por: Shao, Hong Yu, et al.
Publicado: (2023)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Novel immune‐related signature for risk stratification and prognosis in prostatic adenocarcinoma
por: Zhao, Hai‐Bo, et al.
Publicado: (2021)

Association between Acquired Uniparental Disomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer
por: Tuna, Musaffe, et al.
Publicado: (2010)

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

S1PR3, as a Core Protein Related to Ischemic Stroke, is Involved in the Regulation of Blood–Brain Barrier Damage
por: Fan, Xuehui, et al.
Publicado: (2022)

HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer
por: Sun, Xiaodan, et al.
Publicado: (2022)

A combined aging and immune prognostic signature predict prognosis and responsiveness to immunotherapy in melanoma
por: Lv, Wenchang, et al.
Publicado: (2022)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

Identification of a novel ferroptosis-related gene signature associated with prognosis, the immune landscape, and biomarkers for immunotherapy in ovarian cancer
por: Liu, Yilong, et al.
Publicado: (2022)

The emerging role of RNA N6-methyladenosine methylation in breast cancer
por: Zheng, Fangchao, et al.
Publicado: (2021)

Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2− breast cancer: a retrospective cohort study
por: Xie, Yiqun, et al.
Publicado: (2022)

Natural killer cell-related prognosis signature predicts immune response in colon cancer patients
por: Li, Meiqin, et al.
Publicado: (2023)

An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
por: Zhou, Xin, et al.
Publicado: (2014)

Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2011)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

Digital Validation of Breast Biomarkers (ER, PR, AR and HER2) in Cytology Specimens Using Three Different Scanners
por: Salama, Abeer M., et al.
Publicado: (2021)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer
por: Yang, Xia, et al.
Publicado: (2021)

The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis
por: Tang, Yuyao, et al.
Publicado: (2023)

A Novel Epithelial-Mesenchymal Transition Gene Signature Correlated With Prognosis, and Immune Infiltration in Hepatocellular Carcinoma
por: Kong, Weihao, et al.
Publicado: (2022)

A novel necroptosis-related lncRNAs signature effectively predicts the prognosis for osteosarcoma and is associated with immunity
por: Liu, Binfeng, et al.
Publicado: (2022)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6s1honhjk9nm4smcqlcgubc90c